Alimentiv Inc., AcelaBio Inc. and PharmaNest Inc. announce a collaboration to provide precision medicine and artificial intelligence (AI)-powered digital pathology solutions for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH). This collaboration will enable clinical trial sponsors to quantify the histological effects of drugs and gain deeper insights...
bit.bio, the company coding human cells for novel cures, announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter clinical development in 2025. The company also announced three key additions to its Scientific Advisory Board (SAB).
bit.bio’s lead cell therapy candidate (bbHEP01) is in development as...
To help life sciences companies create sustainable value and drive growth, Accenture and Salesforce are investing in the development of Salesforce Life Sciences Cloud including new innovations, assets and accelerators, powered by data and artificial intelligence (AI).
Building on the recently announced Accenture and Salesforce generative AI collaboration, the companies will leverage...
Automation combined with on-line monitoring during the cell expansion step can bring cell therapy manufacturing efficiencies and enable increased patient accessibility and safety
908 Devices Inc., a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a...
Telesis Bio Inc., a leader in automated multi-omic and synthetic biology solutions, announced the commercial release of its BioXp® De novo Cloning and Amplification kit on the BioXp 3250 and BioXp 9600 systems. This cell-free DNA amplification kit provides an efficient automated solution for building and amplifying DNA constructs...
QIAGEN and Element Biosciences, Inc. announced a strategic partnership to offer comprehensive next-generation sequencing (NGS) workflows for the Element AVITI™ System, an innovative sequencing platform.
Element’s AVITI System is a versatile benchtop sequencer offering a combination of performance, cost, and flexibility for a wide range of NGS applications. For customers...
New data supports the potential role of Artificial Intelligence (AI) in predicting patients’ response to immunotherapies in advance of their treatment.
GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80 percent accuracy, based on a pan-cancer cohort, according to findings to be presented at...
Medidata to announce latest innovations to accelerate drug and device development to bring treatments to patients sooner
Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, will host NEXT New York 2023, the premier clinical research conference taking place in New York City...
Multi-year collaboration will enable development of complex, cutting-edge cell therapies and armoring technologies for solid tumor targets
Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian...
TSO 500 ctDNA Version 2 delivers faster turnaround time, greater analytical sensitivity, more streamlined workflow, further enabling precision medicine.
Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight™ Oncology 500 ctDNA v2...
